{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T13:27:50Z","timestamp":1787232470004,"version":"build-2736575974"},"reference-count":5,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bulletin du Cancer"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.bulcan.2026.04.010","type":"journal-article","created":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T11:21:40Z","timestamp":1784114500000},"page":"970-972","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Imlunestrant\u00a0\u2013\u00a0cancer du sein localement avanc\u00e9 ou m\u00e9tastatique RH+\/HER2\u2013, avec mutation activatrice d\u2019ESR1"],"prefix":"10.1016","volume":"113","author":[{"given":"Juliette","family":"Dubois","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fanny","family":"Le Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bulcan.2026.04.010_bib0030","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1186\/s13058-021-01462-3","article-title":"ESR1\u00a0mutation as an emerging clinical biomarker in metastatic hormone receptor-positive breast cancer","volume":"23","author":"Brett","year":"2021","journal-title":"Breast Cancer Res"},{"issue":"7\u20138","key":"10.1016\/j.bulcan.2026.04.010_bib0035","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1016\/j.bulcan.2024.03.005","article-title":"Elacestrant\u00a0\u2013\u00a0cancer du sein localement avanc\u00e9 ou m\u00e9tastatique ER+\/HER2-, pr\u00e9sentant une mutation activatrice d\u2019ESR1 [Elacestrant\u00a0\u2013\u00a0ER+\/HER2-, locally advanced, or metastatic breast cancer with an activating ESR1\u00a0mutation]","volume":"111","author":"Houdou","year":"2024","journal-title":"Bull Cancer"},{"issue":"12","key":"10.1016\/j.bulcan.2026.04.010_bib0040","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1056\/NEJMoa2410858","article-title":"Imlunestrant with or without abemaciclib in advanced breast cancer","volume":"392","author":"Jhaveri","year":"2025","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.bulcan.2026.04.010_bib0045","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1016\/j.annonc.2025.11.018","article-title":"Imlunestrant with or without abemaciclib in advanced breast cancer: updated efficacy results from the phase III EMBER-3 trial","volume":"37","author":"Jhaveri","year":"2026","journal-title":"Ann Oncol"},{"issue":"6","key":"10.1016\/j.bulcan.2026.04.010_bib0025","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1056\/NEJMoa2502929","article-title":"First-line camizestrant for emerging ESR1-mutated advanced breast cancer","volume":"393","author":"Bidard","year":"2025","journal-title":"N Engl J Med"}],"container-title":["Bulletin du Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0007455126003115?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0007455126003115?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T12:57:08Z","timestamp":1787230628000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0007455126003115"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":5,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["S0007455126003115"],"URL":"https:\/\/doi.org\/10.1016\/j.bulcan.2026.04.010","relation":{},"ISSN":["0007-4551"],"issn-type":[{"value":"0007-4551","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Imlunestrant\u00a0\u2013\u00a0cancer du sein localement avanc\u00e9 ou m\u00e9tastatique RH+\/HER2\u2013, avec mutation activatrice d\u2019ESR1","name":"articletitle","label":"Article Title"},{"value":"Bulletin du Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bulcan.2026.04.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Soci\u00e9t\u00e9 Fran\u00e7aise du Cancer. Published by Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}